| pubmed-article:6572004 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6572004 | lifeskim:mentions | umls-concept:C0023270 | lld:lifeskim |
| pubmed-article:6572004 | lifeskim:mentions | umls-concept:C1524059 | lld:lifeskim |
| pubmed-article:6572004 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:6572004 | lifeskim:mentions | umls-concept:C0025519 | lld:lifeskim |
| pubmed-article:6572004 | lifeskim:mentions | umls-concept:C0060662 | lld:lifeskim |
| pubmed-article:6572004 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:6572004 | pubmed:dateCreated | 1983-3-24 | lld:pubmed |
| pubmed-article:6572004 | pubmed:abstractText | Formycin B is a potent inhibitor of growth of the promastigote forms of Leishmania tropica, L. mexicana, L. braziliensis, and L. donovani. The metabolic products formed in these organisms are formycin B 5'-monophosphate and formycin A 5'-mono-, di-, and triphosphates, with formycin A 5'-triphosphate predominating. In addition, formycin A is extensively incorporated into RNA. From the metabolic profile, we conclude that formycin B is first converted to the 5'-monophosphate by the nucleoside phosphotransferase found in Leishmania and is subsequently converted to cytotoxic adenosine nucleotide analogs of formycin A that become incorporated into RNA. The metabolism and mechanism of formycin B appears to be qualitatively similar to that of allopurinol riboside, but quantitative differences and species selectivity suggest that these agents may have a different spectrum of activity as potential anti-leishmanial agents. | lld:pubmed |
| pubmed-article:6572004 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6572004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6572004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6572004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6572004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6572004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6572004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6572004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6572004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6572004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6572004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6572004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6572004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6572004 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6572004 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6572004 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6572004 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6572004 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6572004 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6572004 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6572004 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6572004 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:6572004 | pubmed:issn | 0027-8424 | lld:pubmed |
| pubmed-article:6572004 | pubmed:author | pubmed-author:SantiD VDV | lld:pubmed |
| pubmed-article:6572004 | pubmed:author | pubmed-author:RaineyPP | lld:pubmed |
| pubmed-article:6572004 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6572004 | pubmed:volume | 80 | lld:pubmed |
| pubmed-article:6572004 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6572004 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6572004 | pubmed:pagination | 288-92 | lld:pubmed |
| pubmed-article:6572004 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:6572004 | pubmed:meshHeading | pubmed-meshheading:6572004-... | lld:pubmed |
| pubmed-article:6572004 | pubmed:meshHeading | pubmed-meshheading:6572004-... | lld:pubmed |
| pubmed-article:6572004 | pubmed:meshHeading | pubmed-meshheading:6572004-... | lld:pubmed |
| pubmed-article:6572004 | pubmed:meshHeading | pubmed-meshheading:6572004-... | lld:pubmed |
| pubmed-article:6572004 | pubmed:meshHeading | pubmed-meshheading:6572004-... | lld:pubmed |
| pubmed-article:6572004 | pubmed:year | 1983 | lld:pubmed |
| pubmed-article:6572004 | pubmed:articleTitle | Metabolism and mechanism of action of formycin B in Leishmania. | lld:pubmed |
| pubmed-article:6572004 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6572004 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:6572004 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6572004 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6572004 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6572004 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6572004 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6572004 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6572004 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6572004 | lld:pubmed |
